Erste Group Bank Issues Positive Outlook for Roche Earnings

Roche Holding AG (OTCMKTS:RHHBY) – Equities researchers at Erste Group Bank upped their FY2026 earnings per share (EPS) estimates for Roche in a research note issued to investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $3.14 per share for the year, up from their previous forecast of $3.12. The consensus estimate for Roche’s current full-year earnings is $3.13 per share. Erste Group Bank also issued estimates for Roche’s FY2027 earnings at $3.37 EPS.

RHHBY has been the topic of several other research reports. HSBC downgraded Roche from a “buy” rating to a “hold” rating in a research report on Monday, July 6th. Zacks Research downgraded Roche from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Argus upgraded shares of Roche from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Finally, Morgan Stanley upgraded shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price objective on the stock in a research report on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $51.50.

Roche Price Performance

Shares of RHHBY stock opened at $51.60 on Monday. Roche has a 1 year low of $37.51 and a 1 year high of $60.85. The stock’s 50 day simple moving average is $51.35 and its two-hundred day simple moving average is $52.68. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38.

Institutional Trading of Roche

Several institutional investors and hedge funds have recently made changes to their positions in the business. Confluence Investment Management LLC raised its stake in shares of Roche by 1.2% during the second quarter. Confluence Investment Management LLC now owns 20,925 shares of the company’s stock valued at $1,074,000 after acquiring an additional 258 shares in the last quarter. Oakworth Capital Inc. grew its stake in Roche by 20.8% in the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock worth $86,000 after purchasing an additional 285 shares in the last quarter. Enterprise Financial Services Corp grew its stake in Roche by 6.6% in the first quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company’s stock worth $277,000 after purchasing an additional 345 shares in the last quarter. Archer Investment Corp increased its holdings in Roche by 7.7% during the 1st quarter. Archer Investment Corp now owns 5,598 shares of the company’s stock worth $278,000 after purchasing an additional 398 shares during the period. Finally, Diversified Trust Co raised its position in Roche by 0.8% during the 1st quarter. Diversified Trust Co now owns 59,375 shares of the company’s stock valued at $2,907,000 after purchasing an additional 448 shares in the last quarter.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.